文献速递糖尿病

ORIGIN试验验证2型糖尿病五种亚型分类

Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial.
PubMed 文献 · Diabetologia · 2021-10-21

基于ORIGIN试验7017例多族裔受试者,按诊断年龄、BMI、HbA1c、空腹C肽和GAD抗体分为五种预设亚型。中位随访6.2年,证实严重胰岛素抵抗亚型肾脏事件发生率高于轻度年龄相关亚型,且严重胰岛素缺乏亚型对甘精胰岛素血糖应答更优。

要点

  • 五亚型分类在ORIGIN多族裔队列中可重复,欧洲与拉美人群基线特征相似。
  • 严重胰岛素抵抗亚型较轻度年龄相关亚型肾脏事件风险更高。
  • 严重胰岛素缺乏亚型接受甘精胰岛素较标准治疗高血糖发生减少更明显。

核心结论

  • 五亚型分类在多族裔队列中可重复,肾脏结局和胰岛素应答因亚型而异,支持精准医学应用。

研究设计与样本

  • ORIGIN试验事后分析,纳入7017例已诊断或新诊断糖尿病患者,随机分配甘精胰岛素或标准治疗,中位随访6.2年。

主要发现

  • 严重胰岛素抵抗亚型 vs 轻度年龄相关亚型:CKD 3A期 HR 1.49(95%CI 1.31,1.71),CKD 3B期 HR 2.25(95%CI 1.82,2.78),大量白蛋白尿 HR 1.56(95%CI 1.22,1.99)。
  • 多假设检验校正后,视网膜病变和心血管疾病发生率在亚型间无差异。
  • 亚型与干预交互作用 p=0.001,严重胰岛素缺乏亚型 vs 轻度年龄相关亚型高血糖发生减少13%(甘精胰岛素 OR 1.36 [1.30,1.41];标准治疗 OR 1.49 [1.43,1.57])。

关键数值与推荐

  • 亚型定义基于诊断年龄、BMI、HbA1c、空腹C肽和谷氨酸脱羧酶抗体。
  • 高血糖定义为随机化后平均HbA1c≥6.5%。

临床怎么用

  • 可依据五亚型分类识别肾脏并发症高风险人群(尤其严重胰岛素抵抗亚型)并加强监测。
  • 严重胰岛素缺乏亚型可能从甘精胰岛素治疗中获得更优血糖控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Data analyses from Swedish individuals with newly diagnosed diabetes have suggested that diabetes could be classified into five subtypes that differ with respect to the progression of dysglycaemia and the incidence of diabetes consequences. We assessed this classification in a multiethnic cohort of participants with established and newly diagnosed diabetes, randomly allocated to insulin glargine vs standard care. METHODS: In total, 7017 participants from the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial were assigned to the five predefined diabetes subtypes (namely, severe auto-immune diabetes, severe insulin-deficient diabetes, severe insulin-resistant diabetes, mild obesity-related diabetes, mild age-related diabetes) based on the age at diabetes diagnosis, BMI, HbA1c, fasting C-peptide levels and the presence of glutamate decarboxylase antibodies at baseline. Differences between diabetes subtypes in cardiovascular and renal outcomes were investigated using Cox regression models for a median follow-up of 6.2 years. We also compared the effect of glargine vs standard care on hyperglycaemia, defined by having a mean post-randomisation HbA1c ≥6.5%, between subtypes. RESULTS: The five diabetes subtypes were replicated in the ORIGIN trial and exhibited similar baseline characteristics in Europeans and Latin Americans, compared with the initially described clusters in the Swedish cohort. We confirmed differences in renal outcomes, with a higher incidence of events in the severe insulin-resistant diabetes subtype compared with the mild age-related diabetes subtype (i.e., chronic kidney disease stage 3A: HR 1.49 [95% CI 1.31, 1.71]; stage 3B: HR 2.25 [1.82, 2.78]; macroalbuminuria: HR 1.56 [1.22, 1.99]). No differences were observed in the incidence of retinopathy and cardiovascular diseases after adjusting for multiple hypothesis testing. Diabetes subtypes also differed in glycaemic response to glargine, with a particular benefit of receiving glargine (vs standard care) in the severe insulin-deficient diabetes subtype compared with the mild age-related diabetes subtype, with a decreased occurrence of hyperglycaemia by 13% (OR 1.36 [1.30, 1.41] on glargine; OR 1.49 [1.43, 1.57] on standard care; p for interaction subtype × intervention = 0.001). CONCLUSIONS/INTERPRETATION: Cluster analysis enabled the characterisation of five subtypes of diabetes in a multiethnic cohort. Both the incidence of renal outcomes and the response to insulin varied between diabetes subtypes. These findings reinforce the clinical utility of applying precision medicine to predict comorbidities and treatment responses in individuals with diabetes. TRIAL REGISTRATION: ORIGIN trial, ClinicalTrials.gov NCT00069784.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Pigeyre M, Hess S, Gomez MF, et al. Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. Diabetologia. 2021. PMID: 34676424. doi:10.1007/s00125-021-05567-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。